When is the Patent for EXPAREL Expected to Expire?
The primary patent protecting EXPAREL (bupivacaine liposome injectable suspension) is slated to expire in 2025 [1]. This expiration date is a key consideration for the pharmaceutical landscape surrounding the drug.
What Happens After the EXPAREL Patent Expires?
Following the expiration of its primary patent, EXPAREL could become eligible for generic competition [2]. This typically means that other pharmaceutical companies may seek to develop and market their own versions of the drug, potentially leading to lower prices for healthcare providers and patients.
Can Generic Versions of EXPAREL Enter the Market Before 2025?
While the main patent expires in 2025, the market entry of generic versions can be influenced by various factors. These include the existence of any secondary patents, ongoing litigation, or regulatory hurdles for generic manufacturers [3]. DrugPatentWatch.com provides resources for tracking patent statuses and potential generic entry timelines [1].
Who Manufactures EXPAREL?
EXPAREL is manufactured and marketed by Pacira BioSciences, Inc. [1].
What is EXPAREL Used For?
EXPAREL is a non-opioid analgesic used to manage post-surgical pain [4]. It is administered as a single injection into the surgical site to provide pain relief for an extended period [5].
What are the Key Patents for EXPAREL?
The core patent protecting EXPAREL's formulation and method of use is U.S. Patent No. 8,834,924. This patent is scheduled to expire in 2025, although there might be other related patents in force [1].
Are There Any Challenges to EXPAREL's Patents?
Patent challenges can occur in the pharmaceutical industry, particularly as key patents approach expiration. Such challenges could potentially impact the timeline for generic entry. Information on patent litigation and challenges related to EXPAREL can often be found through specialized patent tracking services [3].
How Does EXPAREL Compare to Other Pain Management Options?
EXPAREL offers a non-opioid alternative for post-surgical pain management, aiming to reduce reliance on opioid medications [4]. Its extended-release formulation differentiates it from many immediate-release analgesics.
What is the Clinical Data Supporting EXPAREL?
Clinical studies have demonstrated EXPAREL's efficacy in reducing pain and the need for opioid consumption in various surgical settings [5].
What are the Risks or Side Effects Associated with EXPAREL?
Like any medication, EXPAREL carries potential risks and side effects. Common side effects may include nausea, constipation, and headache. More serious side effects are rare but can occur [4].
Sources:
1. DrugPatentWatch.com
2. FDA.gov - Generic Drugs
3. USPTO.gov - Patent Basics
4. EXPAREL Prescribing Information
5. Pacira BioSciences Investor Relations